Switch theme
Sign up to access all valuation multiples
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
2015
275
LTM Revenue $340M
LTM EBITDA $126M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Krystal Biotech has a last 12-month revenue (LTM) of $340M and a last 12-month EBITDA of $126M.
In the most recent fiscal year, Krystal Biotech achieved revenue of $291M and an EBITDA of $110M.
Krystal Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Krystal Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $340M | XXX | $291M | XXX | XXX | XXX |
| Gross Profit | $318M | XXX | $270M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $126M | XXX | $110M | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 38% | XXX | XXX | XXX |
| EBIT | $111M | XXX | $103M | XXX | XXX | XXX |
| EBIT Margin | 33% | XXX | 36% | XXX | XXX | XXX |
| Net Profit | $127M | XXX | $89.2M | XXX | XXX | XXX |
| Net Margin | 37% | XXX | 31% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Krystal Biotech's stock price is $126.
Krystal Biotech has current market cap of $3.6B, and EV of $3.0B.
See Krystal Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $3.6B | XXX | XXX | XXX | XXX | $4.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Krystal Biotech has market cap of $3.6B and EV of $3.0B.
Krystal Biotech's trades at 10.4x EV/Revenue multiple, and 27.6x EV/EBITDA.
Equity research analysts estimate Krystal Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Krystal Biotech has a P/E ratio of 28.6x.
See valuation multiples for Krystal Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.6B | XXX | $3.6B | XXX | XXX | XXX |
| EV (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV/Revenue | 8.9x | XXX | 10.4x | XXX | XXX | XXX |
| EV/EBITDA | 24.0x | XXX | 27.6x | XXX | XXX | XXX |
| EV/EBIT | 27.4x | XXX | 29.4x | XXX | XXX | XXX |
| EV/Gross Profit | 9.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 28.6x | XXX | 40.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 25.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKrystal Biotech's last 12 month revenue growth is 44%
Krystal Biotech's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.6M for the same period.
Krystal Biotech's rule of 40 is 79% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Krystal Biotech's rule of X is 146% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Krystal Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 44% | XXX | 44% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 80% | XXX | 225% | XXX | XXX | XXX |
| Rule of 40 | 79% | XXX | 82% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 146% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Krystal Biotech acquired XXX companies to date.
Last acquisition by Krystal Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Krystal Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Krystal Biotech founded? | Krystal Biotech was founded in 2015. |
| Where is Krystal Biotech headquartered? | Krystal Biotech is headquartered in United States of America. |
| How many employees does Krystal Biotech have? | As of today, Krystal Biotech has 275 employees. |
| Who is the CEO of Krystal Biotech? | Krystal Biotech's CEO is Mr. Krish S. Krishnan. |
| Is Krystal Biotech publicy listed? | Yes, Krystal Biotech is a public company listed on NAS. |
| What is the stock symbol of Krystal Biotech? | Krystal Biotech trades under KRYS ticker. |
| When did Krystal Biotech go public? | Krystal Biotech went public in 2017. |
| Who are competitors of Krystal Biotech? | Similar companies to Krystal Biotech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Krystal Biotech? | Krystal Biotech's current market cap is $3.6B |
| What is the current revenue of Krystal Biotech? | Krystal Biotech's last 12 months revenue is $340M. |
| What is the current revenue growth of Krystal Biotech? | Krystal Biotech revenue growth (NTM/LTM) is 44%. |
| What is the current EV/Revenue multiple of Krystal Biotech? | Current revenue multiple of Krystal Biotech is 8.9x. |
| Is Krystal Biotech profitable? | Yes, Krystal Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Krystal Biotech? | Krystal Biotech's last 12 months EBITDA is $126M. |
| What is Krystal Biotech's EBITDA margin? | Krystal Biotech's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Krystal Biotech? | Current EBITDA multiple of Krystal Biotech is 24.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
